following a resubmission:
reslizumab (Cinqaero®) is not recommended for use within NHS Scotland.
Indication under review: as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
Reslizumab, compared with placebo, decreased the incidence of asthma exacerbations and improved lung function in adult patients with severe eosinophilic asthma.
The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Download detailed advice339KB (PDF)
Medicine details
- Medicine name:
- reslizumab (Cinqaero)
- SMC ID:
- 1233/17
- Indication:
- as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
- Pharmaceutical company
- Teva UK Limited
- BNF chapter
- Respiratory system
- Submission type
- Resubmission
- Status
- Not recommended
- Date advice published
- 11 December 2017
In April 2017 SMC reviewed a full submission for reslizumab (Cinqaero), however, the SMC advice was withheld pending product availability. The company subsequently made a resubmission and this was reviewed by SMC in August 2017. Advice for the original submission was not issued as the product was made commercially available in October 2017. Therefore the advice for the resubmission only is published on the SMC website.